The kit, used on the Illumina MiSeqDx System, helps clinicians identify which patients are eligible for treatment with Amgen’s cancer drug Vectibix.
“The [kit] enables labs to implement an in-house solution for precision oncology and signifies that [next generation sequencing] has reached a milestone as a clinical diagnostic platform to aid therapeutic decision-making in oncology,” said Garret Hampton, PhD, Illumina’s executive vice president of clinical genomics.
Illumina will launch the kit in the third quarter of 2017.
More articles on supply chain:
New York City faces critical blood shortage
6 drug, device recalls in June
FDA approves Scibase’s melanoma detection device: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
